Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
Current Hematologic Malignancy Reports|November 9, 2019
Early Management of CMLNaranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 9, 2023
Accelerated-phase CML: de novo and transformedNaranie Shanmuganathan, Timothy P Hughes
Blood|November 16, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 17, 2009
Monitoring disease response to tyrosine kinase inhibitor therapy in CMLTimothy P Hughes, Susan Branford
British Journal of Haematology|June 22, 2022
Asciminib for chronic myeloid leukaemia: Next questionsNaranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 9, 2022
Management of TKI-resistant chronic phase CMLTimothy P Hughes, Naranie Shanmuganathan
Critical Reviews in Oncology/Hematology|January 12, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1Delphine Réa, Timothy P Hughes
Seminars in Hematology|September 30, 2010
Practical considerations for monitoring patients with chronic myeloid leukemiaSusan Branford, Timothy P Hughes
Clinical Lymphoma & Myeloma|September 26, 2009
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reactionTimothy P Hughes, Susan Branford
Current Opinion in Hematology|January 20, 2011
Mutational analysis in chronic myeloid leukemia: when and what to do?Susan Branford, Timothy P Hughes
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
Current Hematologic Malignancy Reports|November 9, 2019
Early Management of CMLNaranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 9, 2023
Accelerated-phase CML: de novo and transformedNaranie Shanmuganathan, Timothy P Hughes
Blood|November 16, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 17, 2009
Monitoring disease response to tyrosine kinase inhibitor therapy in CMLTimothy P Hughes, Susan Branford
British Journal of Haematology|June 22, 2022
Asciminib for chronic myeloid leukaemia: Next questionsNaranie Shanmuganathan, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|December 9, 2022
Management of TKI-resistant chronic phase CMLTimothy P Hughes, Naranie Shanmuganathan
Critical Reviews in Oncology/Hematology|January 12, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1Delphine Réa, Timothy P Hughes
Seminars in Hematology|September 30, 2010
Practical considerations for monitoring patients with chronic myeloid leukemiaSusan Branford, Timothy P Hughes
Clinical Lymphoma & Myeloma|September 26, 2009
Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reactionTimothy P Hughes, Susan Branford
Current Opinion in Hematology|January 20, 2011
Mutational analysis in chronic myeloid leukemia: when and what to do?Susan Branford, Timothy P Hughes
Pageof 21